PL2341047T3 - Pochodna cykloheksanowa i jej farmaceutyczne zastosowanie - Google Patents

Pochodna cykloheksanowa i jej farmaceutyczne zastosowanie

Info

Publication number
PL2341047T3
PL2341047T3 PL09823687T PL09823687T PL2341047T3 PL 2341047 T3 PL2341047 T3 PL 2341047T3 PL 09823687 T PL09823687 T PL 09823687T PL 09823687 T PL09823687 T PL 09823687T PL 2341047 T3 PL2341047 T3 PL 2341047T3
Authority
PL
Poland
Prior art keywords
pharmaceutical use
cyclohexane derivative
cyclohexane
derivative
pharmaceutical
Prior art date
Application number
PL09823687T
Other languages
English (en)
Inventor
Yasuhiro Morita
Katsuhiko Iseki
Yuji Sugawara
Hideyuki Tsutsui
Shunsuke Iwano
Naoki Izumimoto
Tadamasa Arai
Hidetoshi Noda
Chihiro Yoshida
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of PL2341047T3 publication Critical patent/PL2341047T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL09823687T 2008-10-31 2009-10-30 Pochodna cykloheksanowa i jej farmaceutyczne zastosowanie PL2341047T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2008281258 2008-10-31
JP2009176619 2009-07-29
EP09823687.0A EP2341047B1 (en) 2008-10-31 2009-10-30 Cyclohexane derivative and pharmaceutical use thereof
PCT/JP2009/068644 WO2010050577A1 (ja) 2008-10-31 2009-10-30 シクロヘキサン誘導体及びその医薬用途

Publications (1)

Publication Number Publication Date
PL2341047T3 true PL2341047T3 (pl) 2015-03-31

Family

ID=42128936

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09823687T PL2341047T3 (pl) 2008-10-31 2009-10-30 Pochodna cykloheksanowa i jej farmaceutyczne zastosowanie

Country Status (16)

Country Link
US (2) US8247569B2 (pl)
EP (1) EP2341047B1 (pl)
JP (1) JP5522031B2 (pl)
KR (1) KR101313658B1 (pl)
CN (1) CN102203068B (pl)
AU (1) AU2009310807B2 (pl)
BR (1) BRPI0919526B8 (pl)
CA (1) CA2739883C (pl)
DK (1) DK2341047T3 (pl)
ES (1) ES2525708T3 (pl)
MX (1) MX2011004576A (pl)
PL (1) PL2341047T3 (pl)
PT (1) PT2341047E (pl)
RU (1) RU2478621C2 (pl)
TW (1) TWI435874B (pl)
WO (1) WO2010050577A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2554541B1 (en) * 2010-03-31 2015-12-09 Toray Industries, Inc. Therapeutic agent or prophylactic agent for fibromyalgia
JP5783042B2 (ja) * 2010-03-31 2015-09-24 東レ株式会社 蓄尿障害の治療剤又は予防剤
CN102858748B (zh) 2010-04-28 2015-06-17 东丽株式会社 阿尔茨海默病的治疗剂或预防剂
AU2011283462B9 (en) 2010-07-30 2014-09-18 Toray Industries, Inc. Therapeutic agent or prophylactic agent for neuropathic pain
CA2933480C (en) * 2013-12-11 2022-08-23 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
BR112016016674A2 (pt) * 2014-01-29 2017-08-08 Toray Industries Agente terapêutico ou profilático para uso no tratamento de esclerose múltipla
PE20161438A1 (es) 2014-05-01 2017-01-18 Celgene Quanticel Res Inc Inhibidores de desmetilasa 1 especifica a lisina
WO2018181859A1 (ja) * 2017-03-31 2018-10-04 東レ株式会社 抗がん剤誘発末梢神経障害の治療剤又は予防剤
CN115521190A (zh) * 2022-09-20 2022-12-27 阜阳欣奕华制药科技有限公司 乙炔基环己醇的制备方法及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6058981A (ja) * 1983-09-09 1985-04-05 Takeda Chem Ind Ltd 5−ピリジル−1,3−チアゾ−ル誘導体,その製造法およびそれを含んでなる医薬組成物
DE3486009T2 (de) * 1983-09-09 1993-04-15 Takeda Chemical Industries Ltd 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung.
CA2179399A1 (en) * 1993-12-20 1995-06-29 Kiyoshi Taniguchi 4,5-diaryloxazole derivatives
GB9713726D0 (en) 1997-06-30 1997-09-03 Ciba Geigy Ag Organic compounds
WO1999021555A2 (en) 1997-10-27 1999-05-06 Takeda Chemical Industries, Ltd. Adenosine a3 receptor antagonists
AU4308300A (en) * 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
NZ540515A (en) * 2002-12-02 2008-01-31 Astellas Pharma Inc Pyrazole derivatives useful as COX-I inhibitors
RU2005120779A (ru) * 2002-12-02 2006-01-20 Фудзисава Фармасьютикал Ко., Лтд. (JP) Производные пиразола
AU2002953019A0 (en) * 2002-12-02 2002-12-12 Fujisawa Pharmaceutical Co., Ltd. Azole derivatives
JP2007197324A (ja) * 2006-01-23 2007-08-09 Toray Ind Inc 2,4,5−置換−1,3−アゾール誘導体
JPWO2007111323A1 (ja) 2006-03-27 2009-08-13 東レ株式会社 ウレイド誘導体およびその医薬用途
WO2008105383A1 (ja) * 2007-02-26 2008-09-04 Toray Industries, Inc. ピラゾール誘導体およびその医薬用途

Also Published As

Publication number Publication date
PT2341047E (pt) 2015-01-14
EP2341047A4 (en) 2012-08-29
KR20110067053A (ko) 2011-06-20
CN102203068A (zh) 2011-09-28
US20120270906A1 (en) 2012-10-25
JP5522031B2 (ja) 2014-06-18
AU2009310807B2 (en) 2012-02-23
CA2739883A1 (en) 2010-05-06
DK2341047T3 (en) 2015-01-19
EP2341047B1 (en) 2014-10-15
BRPI0919526B8 (pt) 2021-05-25
BRPI0919526A2 (pt) 2015-12-08
BRPI0919526B1 (pt) 2020-03-17
TW201022226A (en) 2010-06-16
ES2525708T3 (es) 2014-12-29
WO2010050577A1 (ja) 2010-05-06
RU2011121809A (ru) 2012-12-10
KR101313658B1 (ko) 2013-10-02
US8247569B2 (en) 2012-08-21
TWI435874B (zh) 2014-05-01
US20110201650A1 (en) 2011-08-18
CN102203068B (zh) 2014-03-19
EP2341047A1 (en) 2011-07-06
US8349874B2 (en) 2013-01-08
JPWO2010050577A1 (ja) 2012-03-29
CA2739883C (en) 2013-05-28
MX2011004576A (es) 2011-06-17
AU2009310807A1 (en) 2010-05-06
RU2478621C2 (ru) 2013-04-10

Similar Documents

Publication Publication Date Title
IL275854A (en) Pharmaceutical composition and its administration
HRP20160579T1 (hr) Spoj indola i njegova farmaceutska upotreba
IL237391A0 (en) Pharmaceutical combination
ZA201105623B (en) Aminopyrazine derivative and medicine
PL2341047T3 (pl) Pochodna cykloheksanowa i jej farmaceutyczne zastosowanie
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
EP2305669A4 (en) AMINO COMPOUNDS AND THEIR PHARMACEUTICAL USE
PL2364975T3 (pl) Nowa pochodna amidu i jej zastosowanie jako lek
IL208771A0 (en) Iminopyridine derivatives and use thereof
HK1152640A1 (en) Pharmaceutical combination
ZA201104710B (en) Pharmaceutical dispenser and use thereof
EP2322505A4 (en) 1-ADAMANTYLAZETIDIN-2-ON DERIVATIVE, PREPARATION THEREOF AND PHARMACEUTICAL PREPARATION THEREWITH
EP2279999A4 (en) RETINOID DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL208824A0 (en) Iminopyridine derivative and use thereof
EP2484661A4 (en) 2,3-DIHYDRO-1H-INDEN-2-YL-UREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF
HK1131039A1 (en) Pharmaceutical use of sophoricoside
EP2274294A4 (en) 5-DIMETHOXY FUMAGILLOL AND ITS DERIVATIVES
HUP0800414A2 (en) Pharmaceutical combination